Alcohol Withdrawal Clinical Trial
Official title:
A Prospective Randomised Controlled Trial of the Effect of Magnesium Sulphate Administration on Red Cell Transketolase Activity in Alcohol Dependent Patients at Risk of Wernicke Korsakoff Syndrome Treated With Thiamine
Patients who suffer Alcohol Use Disorder (AUD) have a 30-80% incidence of thiamine deficiency
causing Wernicke's Encephalopathy (WE).
Intravenous (IV) thiamine replacement is standard practice in the treatment of alcoholic
patients presenting to the Accident & Emergency (A&E) department, however routine
co-supplementation with magnesium (administered IV as magnesium sulphate ), which is required
as a co-factor for thiamine in some metabolic processes, e. g. on the activity of the enzyme
transketolase in red blood cells, is not routine practice in the treatment of these patients.
Without correction of concomitant magnesium deficiency there may be impaired utilisation of
thiamine resulting in a failure to treat WE.
This study is designed to determine if administration of magnesium to AUD patients affects
red cell transketolasae and serum lactate concentrations by itself, or only acts to increase
the effect of thiamine on the activity of this enzyme.
This is a 3- arm randomised, open label, controlled study in a cohort of alcoholic patients
admitted through A&E. Patients will be randomised to concurrent infusion of one of the
following:
- Arm 1: IV thiamine
- Arm 2: IV magnesium sulphate followed by delayed IV thiamine
- Arm 3: IV thiamine and IV magnesium sulphate Thiamine will be administered as IV
Pabrinex, a compound preparation which also contains B vitamins and vitamin C.
Administration of IV Pabrinex is standard care in this patient group and magnesium
sulphate is routinely co-administered at Glasgow Royal Infirmary.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03916939 -
Osteopathic Treatment to Alcohol Withdrawal Syndrome
|
N/A | |
Completed |
NCT04858490 -
Remote Treatment of Alcohol Withdrawal
|
N/A | |
Not yet recruiting |
NCT04997330 -
Evaluation of Bilateral HF-rTMS on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction
|
N/A | |
Recruiting |
NCT04876443 -
Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
|
||
Completed |
NCT05131334 -
Auricular Vagal Stimulation in Alcohol Craving
|
N/A | |
Completed |
NCT02349477 -
Gabapentin for Alcohol Relapse Prevention
|
Phase 2 | |
Terminated |
NCT01937364 -
Preventing Alcohol Withdrawal With Oral Baclofen
|
Phase 2 | |
Completed |
NCT05393544 -
Digitally Assisted Recovery Coach
|
N/A | |
Completed |
NCT00523185 -
A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal
|
N/A | |
Completed |
NCT01573052 -
Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
|
Phase 4 | |
Enrolling by invitation |
NCT06173973 -
Effects of Ketone Supplementation on Acute Alcohol Withdrawal
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03737864 -
NCARE, Transition to Recovery
|
N/A | |
Recruiting |
NCT03878225 -
Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans?
|
N/A | |
Terminated |
NCT03586089 -
Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome
|
N/A | |
Recruiting |
NCT04156464 -
Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit
|
Phase 4 | |
Completed |
NCT02202148 -
Liver Stiffness Measurement in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal
|
N/A | |
Completed |
NCT02251912 -
Oxytocin Treatment of Alcohol Dependence
|
Phase 2 | |
Completed |
NCT01212185 -
Oxytocin Treatment of Alcohol Withdrawal
|
Phase 1 | |
Recruiting |
NCT04793685 -
Prazosin for Alcohol Use Disorder With Withdrawal Symptoms
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04159909 -
Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal
|
N/A |